anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
For all pediatric patients weighing less than 45 kg with severe or life-threatening infections (e.g., anthrax, Rocky Mountain spotted fever), the recommended dosage is 2.2 mg/kg of body weight administered every 12 hours. Children weighing 45 kg or more should receive the adult dose (see WARNINGS and PRECAUTIONS). 

For pediatric patients with less severe disease (greater than 8 years of age and weighing less than 45 kg), the recommended dosage schedule is 4.4 mg/kg of body weight divided into two doses on the first day of treatment, followed by a maintenance dose of 2.2 mg/kg of body weight (given as a single daily dose or divided into twice daily doses). For pediatric patients weighing over 45 kg, the usual adult dose should be used. 

In the treatment of inhalational anthrax (post-exposure) the recommended dose is 2.2 mg/kg of body weight, twice a day in children weighing less than 45 kg. Parenteral therapy is only indicated when oral therapy is not indicated and should not be continued over a prolonged period of time. Oral therapy should be instituted as soon as possible. Therapy must continue for a total of 60 days.
The invention relates to soluble powder for preventing and treating colibacillosis of poultry, comprising sulfachlorpyridazine sodium, trimethoprim and auxiliary materials. The inventive medicament is mainly used to prevent and treat colibacillosis of poultry. The sulfachlorpyridazine sodium and trimethoprim have compatibility when used together. The trimethoprim is used as an antisepsis synergist of sulfonamides when resisting bacteria, thus strengthening medicament effect of sulfachlorpyridazine sodium. The sulfachlorpyridazine sodium and trimethoprim cooperate to effectively treat colibacillosis. The soluble powder has good absorption and relatively high safety when orally taken.
Alternate-day fasting (ADF) has been reported to reduce body weight, neuroinflammation, and oxidative stress damage. However, it is not known whether ADF affects obesity-induced anxiety-like behavior. Here, male C57BL/6 mice were given an alternate fasting and high-fat diet (HFD) or standard chow diet (SD) every other day for 16 or 5 weeks. After the intervention, the degree of anxiety of the mice was evaluated by the open field test (OFT) and the elevated plus maze (EPM) test. Pathological changes in the hippocampus, the expression of Sirt1 and its downstream protein monoamine oxidase A (MAO-A) in the hippocampus, and the expression of 5-hydroxytryptamine (5-HT) were detected. Compared with HFD-fed mice, HFD-fed mice subjected to ADF for 16 weeks had a lower body weight but more brown adipose tissue (BAT), less anxiety behavior, and less pathological damage in the hippocampus, and lower expression of Sirt1 and MAO-A protein and higher 5-HT levels in the hippocampus could be observed. In addition, we noted that long-term ADF intervention could cause anxiety-like behavior in SD mice. Next, we changed the intervention time to 5 weeks. The results showed that short-term ADF intervention could reduce the body weight and increase the BAT mass of SD mice, but it did not affect anxiety. These results indicated that long-term ADF ameliorated obesity-induced anxiety-like behavior and hippocampal damage, but caused anxiety in normal-weight mice. Short-term ADF did not produce adverse emotional reactions in normal-weight mice. Here, we might provide new ideas for the treatment of obesity-induced anxiety.
PURPOSE: Provided is an extract of Polygonum multiflorum Thunb. which involves the activity of lowering the blood sugar, and is well adapted for use in treating the diseases related to diabetes, and in making food additives. CONSTITUTION: A method of manufacturing the extract of Polygonum multiflorum Thunb. comprises the steps of: extracting Polygonum multiflorum Thunb. at 0-100 deg.C with a solvent selected from water, polar organic solvent or a mixture thereof; removing the solid component from the extracted solution through centrifuging or filtering; and removing the extracting solvent from the extracted solution, followed by purifying it. The polar organic solvent is short chain alcohol with C1-C4.
PURPOSE: A therapeutic agent of hyperhidrosis is provided which can treat the hyperhidrosis by administering orally for from 3 days to 27 days, without any side effect or recurrence. The therapeutic agent overcomes problems or side effects, which the prior arts have, such as burning, dysphoria cutitis etc. CONSTITUTION: The therapeutic agent of hyperhidrosis comprises an effective amount of a composition comprising the following elements: 20-40 pts.wt. of Gypsum Fibrosum, 5-20 pts.wt. of Rhizoma Anemarrhenae, 1-5 pts.wt. of Radix Glycyrrhizae, 3-10 pts.wt. of Fructus Oryzae and 500 pts.wt. of water. Preferably, a preparation method of the agent for dosage comprises the steps of: adding 30 g of the soft Gypsum Fibrosum, 10 g of Rhizoma Anemarrhenae, 3 g of Radix Glycyrrhizae, 6 g of Fructus Oryzae and 500 ml of water to a proper container; extracting by heating slowly at low temperature; filtering the extract to obtain 150 ml of the filtrate, when the Fructus Oryzae is boiled well.
Xanthoma typically occurs in the subcutaneous tissues, with rare cases of xanthoma in the joints. However, the case of knee joint osteonecrosis combined with xanthoma is even more uncommon. In this article, we described a 50-year-old female patient who suffered xanthoma in the knee joint on the basis of osteonecrosis of the knee joint. The primary clinical symptoms were knee joint pain and limited mobility. The patient initially received conventional treatment for osteonecrosis. However, there was no significant improvement. Later, we found a synovial xanthoma in the patient's knee. Finally, she underwent arthroscopic excision of the knee joint synovial xanthoma. Following the procedure, her VAS score decreased from 7 to 2, and knee joint mobility increased from 10-103° to 10-140°. Through our follow-up, the patient did not exhibit symptom recurrence. This case is valuable as it provides a feasible therapeutic approach for future clinical applications.
Before standard-of-care chemotherapy, a leukapheresis will be performed and monocytes will be used for differentiation to DCs using specific cytokines. Allogeneic tumor lysate (Pheralys) loaded autologous DCs (MesoPher) will be re-injected 3 weeks after completing chemotherapy, 2 times every other week. Four weeks after the first injection with DCT, patients will undergo eP/D surgery and receive three bi-weekly injections with DCT (starting 4 weeks after surgery). If there is a surplus of vaccinations, a 6th and 7th vaccination at 3 and six months after the last vaccination could be considered by the treating physician.
Participants randomized to the control condition will be receive a Spanish-language version of an alcohol education brochure. Participants will be encouraged to read the brochure. The brochure will provide information about defining heavy drinking, harmful effects of drinking and symptoms of an alcohol use disorder. Control group participants will also receive a list of available clinics and resources from Providence staff. After the baseline visit participants in the control group will be contacted by phone twice over the next 4 weeks by the promotores to remind them about the 3-month follow-up appointment.
Systems, devices, and methods for securing food integrity and safety during a delivery process. The method includes receiving an order placed by a consumer for food delivery from a provider. The order includes at least one item. The method also includes determining, from a provider profile, one or more ingredients contained in the at least one item. The method further includes retrieving, based on the one or more ingredients, guidelines comprising procedures for handling, packaging, and delivery of items containing the one or more ingredients. Additionally, the method includes generating instructions for packaging, handling, and delivery of the at least one item based on the guidelines. The method includes transmitting, over a network, an electronic copy of the instructions.
O-trimethyl-silyl ethers of the N-carboxy-anhydrides of serine, threonine, tyrosine and hydroxy-proline and process for prepn. thereof. - The ethers are used in the synthesis of polypeptides. The ether group blocks the active hydrogen atom of the hydroxyl group so that undesirable side reactions do not occur when an amino acid or peptide is reacted with an N-carboxy-amino acid anhydride under controlled conditions to form an N-carboxy peptide which is then decarboxylated. The trialkyl silyl group has the advantage over conventional blocking groups e.g. benzyl, in that it is removed during the course of the coupling reaction, and thus does not require an additional step for its removal. - (1) O-trimethylsilyl serine N-carboxy anhydride - (2) O-trimethylsilyl threonine N-carboxy anhydride - (3) O-trimethylsilyl tyrosine N-carboxy anhydride - (4) O-trimethylsilyl hydroxyproline N-carboxy anhydride.
People with advanced chronic kidney disease (CKD) are at risk for malnutrition, which is associated with significantly increased mortality. Impairments in olfaction and taste are under-recognized and under-addressed symptoms that affect this population. Olfaction and taste influence appetite and nutritional status and represent a unique target for study and intervention. Small cross-sectional studies have shown a higher prevalence of olfactory (up to 56%) and taste disturbances (up to 35%) among patients with CKD compared with the general population, but little is known about longitudinal change in olfaction and taste in this population. Additionally, there is a lack of understanding about why these sensory disturbances more commonly occur in people with CKD, although there is speculation that uremia may contribute.

This information gained from this study will address these gaps in knowledge by studying longitudinal changes in olfaction and taste and their associations with concurrent and future nutritional and functional status. Additionally this study will attempt to identify potentially modifiable risk factors associated with olfactory and taste impairment.
Sorafenib (SOR)-naïve patients receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1). In clinical practice, dose reduction of SOR is often required. Therefore, on C1D15, the clinician will dose-reduce sorafenib based on toxicity and hydroxychloroquine (HCQ) 400 mg PO daily will be started. C2D1 of each cohort, toxicity of HCQ will be assessed. Dose reductions due to adverse events (AEs) to each agent are allowed for SOR per standard of care and/or HCQ for grade 3+ AE.
We previously reported that immunoglobulin superfamily member 9 (IGSF9) as a tumor specific immune checkpoint promoted the tumor immune escape, however, as an adhesion molecule, whether IGSF9 promotes tumor invasion and metastasis has not been reported. Here, the full length, the intracellular domain (ID) not extracellular domain (ECD) of IGSF9 could alter tumor cell morphology from a flat and polygonal shape to elongated strips, suggesting that IGSF9 signal pathway has the potential to mediate epithelial-to-mesenchymal transition (EMT). Real-time PCR and western blotting also showed that the mesenchymal markers were significantly up-regulated, and the epithelial markers were significantly down-regulated in IGSF9 and IGSF9-ID groups. Meanwhile, immunofluorescence showed that β-catenin was clearly translocated into the nucleus in IGSF9 and IGSF9-ID groups. The in vitro and in vivo data showed that IGSF9, IGSF9-ID and ECD could promote tumor invasion and metastasis. Mechanistically, IGSF9-ID could recruit GSK-3β to result in the accumulation and nuclear translocation of β-catenin to trigger EMT. Anti-IGSF9 could significantly inhibit the invasion and metastasis, and IGSF9 is an effective candidate for lung cancer therapy.
Subjects will attend 2-hour weekly sessions for 6- weeks. Participants will continue to use the DMN application for 4-weeks after the intervention is complete.
AIMS: Renal fibrosis is an important pathophysiological process commonly observed in patients chronic kidney disease (CKD). Angiotensin II (Ang II) is a major risk factor for CKD in part by promoting renal fibrosis. In the present study we investigated Brahma-Related Gene 1 (BRG1, encoded by Smarca4) in Ang II induced pro-fibrogenic response in renal fibroblasts.
METHODS AND MATERIALS: CKD was induced by chronic angiotensin II infusion. Fibroblast- and myofibroblast-specific BRG1 deletion was achieved by crossing the BRG1f/f mice to the Col1a1-CreERT2 mice and the Postn-CreERT2 mice, respectively.
KEY FINDINGS: BRG1 expression was up-regulated when fibroblasts were exposed to Ang II in vitro and in vivo. BRG1 silencing in primary renal fibroblasts blocked transition to myofibroblasts as evidenced by down-regulation of myofibroblast marker genes and reduction in cell proliferation, migration, and contraction. Consistently, deletion of BRG1 from fibroblasts or from myofibroblasts significantly attenuated renal fibrosis in mice subjected to chronic Ang II infusion. Transcriptomic analysis indicated that BRG1 primarily regulated expression of genes involved in cell migroproliferative behavior and extracellular matrix remodeling. Importantly, administration of PFI-3, a small-molecule BRG1 inhibition, markedly ameliorated Ang II induced renal fibrosis in mice.
SIGNIFICANCE: Our data support a role for BRG1 in Ang II induced fibrogenic response in renal fibroblasts and suggest that targeting BRG1 could be considered as a reasonable approach for the intervention of CKD.
This is an in vivo positron emission tomography (PET) study of regional cerebral dopamine and blood flow in normal volunteers, persons with Parkinson s disease (both familial and sporadic), and those with schizophrenia spectrum disorders. The latter also sign consent for NIH approved protocol 89-M-0160, "Inpatient Evaluation of Neuropsychiatric Patients," PI: Daniel Eisenberg, M.D. Using PET with 6-\[F-18\] Fluoro-L-dopa (FDOPA) and (15)0-H2O in a single scan session, both presynaptic dopaminergic function and regional cerebral blood flow (rCBF) are assessed. The kinetic rate constant (Ki) for presynaptic dopaminergic uptake in striatum and other regions is calculated. We compare Ki across subject groups and relate the findings to rCBF. Findings are also related to allelic variation in genes of interest, for determination of which participants sign separate consent for NIH approved protocol 95-M-0150 Neurobiological Investigation of Patients with Schizophrenia Spectrum Disorders and Their Siblings, PI: Karen F. Berman, MD. We also draw comparisons between subjects with inherited vs. sporadic Parkinson s disease to determine whether the PET phenotype is the same in both groups, and we compare system-level, circuit-based pathophysiology across PD and schizophrenia groups. Each subject is further screened with an MRI to rule out structural abnormalities and also to further delineate areas of interest in the PET scans.
FIELD: homeopathic treatment. SUBSTANCE: invention is used in a system treatment combining homeopathic methods and traditional therapy. Drug of invention contains, as material carrier, therapeutically active substance in therapeutic dose. This material carrier is provided with information of biologically active substance prepared through homeopathic way. Biologically active substance in the form of potentialized homeopathic preparation is combined with drug and has the same chemical formula as the latter and similar medicinal form. New drugs are characterized with enhanced biophysical properties and possess elevated therapeutic efficiency. EFFECT: increased therapeutic efficiency of drug.
Participants will receive gemcitabine 1000 mg/ meter squared (m\^2) and nab-paclitaxel 125 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each treatment cycle. Treatment will be administered over a 28-day cycle, for up to 6 cycles.
PURPOSE:To produce high-purity akalone exhibiting a xanthine oxidase inhibitory effect and, therefore, useful for preventing hyperuricemia and for improving gout at low cost by culturing an akalone-producing microorganism belonging to Flavobacterium. CONSTITUTION:An akalone-producing microorganism [e.g. Flavobacterium N-81106 (Bikoken stipulation No. 12782)] belonging to Flavobacterium is cultured and akalone is subsequently collected from the cultured material by a known method. In addition, the above-mentioned culture is carried out preferably at 22 to 30 deg.C and pH6 to 8 by the submerged aeration culture method. The culture period is recommendably 1 to 8 days in general.
Phenoxyalkylamines of the general formula <FORM:1014348/C2/1> wherein R and R1 are each a hydrogen, chlorine or bromine atom, a trifluoromethyl radical or a C1- 4 alkyl or alkoxy group, X is a divalent alkylene group having the formula <FORM:1014348/C2/2> R2 is a hydrogen atom or a methyl radical and R3 is a methyl radical, or R2, R3 and the nitrogen atom together form a pyrrolidine or piperidine ring, may be prepared by condensing the appropriate phenol (as its sodium salt) with an aminoalkyl halide to give the product directly or, alternatively, the phenol may be condensed with an a -haloalkanoamide to give the corresponding a -phenoxyamide which may then be reduced to the amine, e.g. with LiAlH4. The products may be converted to acid addition salts.  The Specification also discloses the preparation of N,N - dimethyl - a  - bromo - propionamide by reacting a -bromopropionyl bromide with dimethylamine; the preparation of 2-(2,6-dichlorophenoxy) - N,N,1 - trimethylethylamine by reacting 2,6-dichlorophenol with chloroacetone to give 2,6-dichlorophenoxyacetone which is reacted with dimethylamine and formic acid to give the required product; and the preparation of N-monomethyl-2-(2,6-dichlorophenoxy) - propylamine by heating the corresponding N,N-dimethyl compound with cyanogen bromide and hydrolysing the product.ALSO:Pharmaceutical compositions in unit dosage form comprise a carrier and phenoxyalkylamine (or an acid addition salt thereof) of the general formula <FORM:1014348/A5-A6/1> wherein R and R1 are each a hydrogen, chlorine or bromine atom a trifluoromethyl radical or a C1-4 alkyl or alkoxy radical, X is a divalent alkylene group having the formula <FORM:1014348/A5-A6/2> or <FORM:1014348/A5-A6/3> R2 is a hydrogen atom or a methyl radical and R3 is a methyl radical or R2, R3 and the nitrogen atom together form a pyrrolidine or peperidine ring.  The compositions-which have anti-depressant activity-may be in conventional forms for oral or parenteral administration, e.g. a tablet, powder, capsules, troche, lozenge, or injectable preparation.
Functional Gastrointestinal Diseases (FGID) are a family disorders that are characterized by gastrointestinal symptoms in the absence of readily identifiable organic pathology. Examples of FGID include irritable bowel syndrome, rumination syndrome, and function constipation. These disorders are classically thought to stem from dysfunction of the enteric nervous system. However, there is a growing recognition that multiple factors play a role in the genesis of FGIDs. This idea is encapsulated by the "biopsychosocial" model of disease, and is supported by a body of literature which has identified higher rates of FGID in patients with anxiety, depression, post-traumatic stress disorder, agoraphobia, and other psychosocial dysfunction.

Recurrent Abdominal Pain and Irritable Bowel Syndrome are major causes of pediatric morbidity. Over a third of children and adolescents report recurrent abdominal pain, and the overall prevalence of non-organic abdominal pain has been noted to be over 75% 1 2. A large subset of these children report symptoms that are consistent with irritable bowel syndrome. Management of these children is complex and includes medical, dietary, and behavioral interventions. Medical therapy often revolves around the use of antispasmodics, probiotics, and antidepressants. The data supporting their use, however has been mixed.

Over the last twenty years behavioral therapies such as cognitive behavioral therapy (CBT) and hypnotherapy (HT) have come to light as major treatment modalities for functional gastrointestinal disease. In a large multicenter randomized controlled trial Levy et al compared 3-session CBT to a control intervention and noted significant improvements and pain and function in children 3. Similar results have been published in multiple smaller trials 4-8. Likewise, Vlieger et al compared hypnotherapy to standard medical therapy in 53 children with irritable bowel syndrome. They found that, while both interventions resulted in improved pain scores, the hypnotherapy group demonstrated lasting clinical improvement at 1 year followup 9. Five year follow-up data has recently been published and revealed that significantly more of the hypnotherapy group remained in remission without any further intervention 10. A growing body of literature is available validating the use of hypnotherapy in irritable bowel syndrome in adults, and pain syndromes more generally 11-14.

These therapies can be viewed as complementary to one another. CBT involves a very deliberate conscious understanding of ones disease process and triggers and focuses on successful pain mitigation measures. HT recruits the imagination with utilization of therapeutic imagery to down regulate inappropriate pain responses. Our center has developed a collaborative approach, utilizing both CBT and HT for the treatment of refractory IBS. To our knowledge no work has been done assessing the efficacy of such a collaborative approach using both CBT and HT in children with functional gastrointestinal disease. We therefore propose the following randomized case-control crossover trial to assess the efficacy our combined program.
Nabumetone, USP is a naphthylalkanone designated chemically as 4-(6-methoxy-2-naphthalenyl)-2-butanone. It has the following structure: 

Nabumetone, USP is a white to off-white crystalline substance. It is nonacidic and practically insoluble in water, but soluble in alcohol and most organic solvents. It has an n-octanol: phosphate buffer partition coefficient of 2,400 at pH 7.4. 

Each tablet, for oral administration, contains either 500 mg or 750 mg of nabumetone, USP. In addition, each tablet contains the following inactive ingredients: colloidal silicon dioxide, corn starch, hypromellose, magnesium stearate, povidone, sodium lauryl sulfate, sodium starch glycolate, titanium dioxide and triacetin. The 500 mg tablets also contain talc and the 750 mg tablets also contain iron oxide red.
A wound dressing has a flexible substrate 2 with a first face 3 and an opposing face 4. A first electrode 9 and a second electrode 10 are located on the first face, the first electrode defining a recessed area and the second electrode protruding into the recessed area. At least one of the electrodes is coated with an electrically conductive material for promoting a redox reaction. When a microcurrent flows at -0.45V the dressing generates hydrogen peroxide by reducing atmospheric oxygen dissolved in the coating. The coating may be a conjugated polymer such as PEDOT:PSS, and be topped with hydrogel. The dressing may include a Ag/AgCl reference electrode and a potentiostat. The first and second electrodes may interdigitate, or zig-zag (figure 7B), or form a circle within an annulus (figure 10), or otherwise interlock; they may be secured to the substrate by adhesive 5.